Selectivity and Anti-Parkinson’s Potential of Thiadiazolidinone RGS4 Inhibitors
- 6 April 2015
- journal article
- research article
- Published by American Chemical Society (ACS) in ACS Chemical Neuroscience
- Vol. 6 (6) , 911-919
Abstract
Many current therapies target G protein coupled receptors (GPCR), transporters, or ion channels. In addition to directly targeting these proteins, disrupting the protein–protein interactions that localize or regulate their function could enhance selectivity and provide unique pharmacologic actions. Regulators of G protein signaling (RGS) proteins, especially RGS4, play significant roles in epilepsy and Parkinson’s disease. Thiadiazolidinone (TDZD) inhibitors of RGS4 are nanomolar potency blockers of the biochemical actions of RGS4 in vitro. Here, we demonstrate the substantial selectivity (8- to >5000-fold) of CCG-203769 for RGS4 over other RGS proteins. It is also 300-fold selective for RGS4 over GSK-3β, another target of this class of chemical scaffolds. It does not inhibit the cysteine protease papain at 100 μM. CCG-203769 enhances Gαq-dependent cellular Ca2+ signaling in an RGS4-dependent manner. TDZD inhibitors also enhance Gαi-dependent δ-OR inhibition of cAMP production in SH-SY-5Y cells, which express endogenous receptors and RGS4. Importantly, CCG-203769 potentiates the known RGS4 mechanism of Gαi-dependent muscarinic bradycardia in vivo. Furthermore, it reverses raclopride-induced akinesia and bradykinesia in mice, a model of some aspects of the movement disorder in Parkinson’s disease. A broad assessment of compound effects revealed minimal off-target effects at concentrations necessary for cellular RGS4 inhibition. These results expand our understanding of the mechanism and specificity of TDZD RGS inhibitors and support the potential for therapeutic targeting of RGS proteins in Parkinson’s disease and other neural disorders.Keywords
Funding Information
- National Institute of Diabetes and Digestive and Kidney Diseases (P60 DK020572)
- National Institute on Drug Abuse (R01 DA023252)
- National Cancer Institute (P30 CA046592)
This publication has 45 references indexed in Scilit:
- Advances in G Protein-Coupled Receptor Allostery: From Function to StructureMolecular Pharmacology, 2014
- Biased Agonism at G Protein‐Coupled Receptors: The Promise and the Challenges—A Medicinal Chemistry PerspectiveMedicinal Research Reviews, 2014
- Structure-Based Drug Design for G Protein-Coupled ReceptorsProgress in Medicinal Chemistry, 2014
- Insights into the structure of class B GPCRsTrends in Pharmacological Sciences, 2014
- Development of allosteric modulators of GPCRs for treatment of CNS disordersNeurobiology of Disease, 2014
- Recent Trends and Future Prospects in Computational GPCR Drug Discovery: From Virtual Screening to PolypharmacologyCurrent Topics in Medicinal Chemistry, 2013
- Regulators of G Protein Signaling Proteins as Targets for Drug Discovery2010
- Small Molecule Protein–Protein Interaction Inhibitors as CNS Therapeutic Agents: Current Progress and Future HurdlesNeuropsychopharmacology, 2008
- REGULATORs OF G PROTEIN SIGNALING & DRUGS OF ABUSEMolecular Interventions, 2005
- Regulators of G-Protein signalling as new central nervous system drug targetsNature Reviews Drug Discovery, 2002